Heather N. Hayenga

This study shows NAB2-STAT6 fusion proteins form nuclear condensates that drive transcriptional changes in SFT, and Mithramycin A disrupts these condensates.

This study identifies BET inhibitors Mivebresib and BMS-986158 as effective anti-SFT agents through high-throughput screening and preclinical models.

This paper demonstrates a method to selectively open the blood-brain barrier using light-stimulated nanoparticles targeting tight junctions, enabling macromolecule and gene therapy vector delivery without neurotoxicity.